Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The weight-loss pill is aimed at helping people lose weight and lower their blood sugar. Management at Eli Lilly says they aim to announce within the current quarter, the trial results for the drug that is being tested in overweight and obese people.
Eli Lilly says that it plans to submit the non-diabetes Phase 3 clinical trial data to global regulatory agencies by the end of the year, and seek approval to begin selling the medication on a commercial basis in the U.S. and other jurisdictions.
The U.S. Food and Drug Administration (FDA) typically makes new drug approval decisions 10 months after a pharmaceutical company makes a submission or application for regulatory approval.
Game-Changer?
Many analysts who follow LLY stock expect the approval of the weight-loss pill to be a game-changer for the company and the entire weight-loss industry. Currently, weight-loss medications are taken by injection that involves people administering needles to themselves.
A once per day pill is seen as a much more palatable way for people to take weight-loss drugs, say analysts. Wall Street investment bank Morgan Stanley (MS) recently forecast that the global market for weight-loss medications could reach $150 billion by 2035, with much of that growth coming from pill versions of the prescription drugs.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,006.80 implies 26.36% upside from current levels.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
8 hours ago
- Business Insider
BigBear.ai Stock (BBAI) Up 82% YTD, Technical Indicators Still Suggest 'Strong Buy'
(BBAI) shows growth potential given its expansion into commercial markets and AI vision tech through acquisitions. Also, the company has secured several key contracts, including one with the U.S. Department of Defense, boosting its reputation and financial standing. BBAI stock has soared 81.8% year-to-date. Despite these gains, technical indicators suggest that BBAI stock is a Strong Buy, implying further upside from current levels. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. BBAI is an AI-driven analytics company that provides decision intelligence solutions for defense, government, and commercial sectors. Analyzing Stock's Technical Indicators According to TipRanks' easy-to-understand technical analysis tool, BBAI stock is currently on an upward trend. The Moving Average Convergence Divergence (MACD) indicator, which helps understand momentum and potential price changes, signals a Buy. Further, the stock's 50-day Exponential Moving Average (EMA) is 5.21, while its price is $8.13, implying a bullish signal. Also, its shorter duration EMA (20 days) signals an uptrend. Another technical indicator, the Rate of Change (ROC), is a momentum-based technical indicator used to measure the percentage change in a stock's price between the current price and the price from a specific number of periods earlier. Typically, a ROC above zero confirms an uptrend. BBAI stock currently has an ROC of 48.02, which signals a Buy. Is BBAI Stock a Good Buy? Turning to Wall Street, BBAI stock has a Moderate Buy consensus rating based on two Buys and two Holds assigned in the last three months. At $5.83, the average price target implies 28.4% downside potential.
Business Insider
8 hours ago
- Business Insider
Morgan Stanley Remains a Hold on Qube Holdings (1K1)
Morgan Stanley analyst Robert Koh maintained a Hold rating on Qube Holdings today and set a price target of A$4.20. The company's shares closed last Tuesday at €2.36. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Koh is a 3-star analyst with an average return of 2.3% and a 52.05% success rate. Koh covers the Energy sector, focusing on stocks such as Origin Energy Limited, Ampol Limited, and Santos Limited. Qube Holdings has an analyst consensus of Moderate Buy, with a price target consensus of €2.51, representing a 6.36% upside. In a report released on July 14, RBC Capital also maintained a Hold rating on the stock with a A$4.30 price target. 1K1 market cap is currently €4.2B and has a P/E ratio of 30.69.
Business Insider
8 hours ago
- Business Insider
Ord Minnett Sticks to Its Buy Rating for BlueBet Holdings Ltd. (BBT)
In a report released today, Phillip Chippindale from Ord Minnett maintained a Buy rating on BlueBet Holdings Ltd., with a price target of A$0.46. The company's shares opened today at A$0.31. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Chippindale is an analyst with an average return of -0.8% and a 39.01% success rate. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BlueBet Holdings Ltd. with a A$0.47 average price target.
